These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 21487088

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ, Ondo WG, Dashtipour K, Swope DM.
    Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
    [Abstract] [Full Text] [Related]

  • 5. Tetrabenazine.
    Fasano A, Bentivoglio AR.
    Expert Opin Pharmacother; 2009 Dec; 10(17):2883-96. PubMed ID: 19929707
    [Abstract] [Full Text] [Related]

  • 6. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
    Med Lett Drugs Ther; 2018 Apr 23; 60(1545):65-68. PubMed ID: 29667946
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Tetrabenazine (tetrabenazine Orphan) orally].
    J Pharm Belg; 2014 Dec 23; (4):49-50. PubMed ID: 25562927
    [No Abstract] [Full Text] [Related]

  • 9. Predictive factors for tolerability of tetrabenazine in patients with hyperkinetic movement disorders.
    Sahin T, Yilmaz R, Akbostanci MC.
    Parkinsonism Relat Disord; 2020 May 23; 74():36-37. PubMed ID: 32311641
    [No Abstract] [Full Text] [Related]

  • 10. Tetrabenazine and movement disorders.
    Asher SW, Aminoff MJ.
    Neurology; 1981 Aug 23; 31(8):1051-4. PubMed ID: 6455607
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.
    Lerner PP, Miodownik C, Lerner V.
    Psychiatry Clin Neurosci; 2015 Jun 23; 69(6):321-34. PubMed ID: 25556809
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Deuterated Drug Molecules: Focus on FDA-Approved DeutetrabenazinePublished as part of the Biochemistry series "Biochemistry to Bedside".
    DeWitt SH, Maryanoff BE.
    Biochemistry; 2018 Feb 06; 57(5):472-473. PubMed ID: 29160059
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.
    Jankovic J, Clarence-Smith K.
    Expert Rev Neurother; 2011 Nov 06; 11(11):1509-23. PubMed ID: 22014129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.